Useful Resources
To better understand the specificities of ATMPs and navigate its complex ecosystem, this page collects a series of educational documents in different supports (videos, files, URLs, etc.).
Videos
Expert briefing sessions on cell and gene therapies – Playlist on the TRANSFORM YouTube channel
-
Modules 1&2: Understanding the promise of cell&gene therapies and its value for patients and healthcare system
-
Bakhuti Shengelia (Novartis) – Gene Therapies: Transforming the lives of patients today
-
Avril Daly (RI) – The value of cell&gene therapies for patients and healthcare systems
-
Prof. Francesco Muntoni (UCL) – Understanding the promise of cell&gene therapies
-
Brid Carberry (Novartis) – How are cell&gene therapies manufactured?
-
Module 3: How can we maximise the value of cell&gene therapies through early detection?
-
Martine Pergent (IPOPI) – How can we maximise the value of cell&gene therapies through early detection?
-
Tim Wilsdon (CRA) – How can we maximise the value of cell&gene therapies through early detection?
-
Module 4: Towards better use and exchange of RWE for cell&gene therapies
-
Elke Grooten (Novartis) – Towards better use and exchange of RWE for cell&gene therapies
-
Guillaume Byk (European Commission) – Towards better use and exchange of RWE for cell&gene therapies
-
Jo De Cock (INAMI-RIZIV) – Towards better use and exchange of RWE for cell&gene therapies
-
Prof Alessandra Ferlini (University of Ferrara) – Towards better use and exchange of RWE for cell&gene therapies
-
Alexander Natz (Secretary-General, EUCOPE) – Gene&cell therapy regulation and what it means for the revision of the pharma legislation
-
Martina Schussler-Lenz (Chair of EMA Committee for Advanced Therapies (CAT) – Gene&cell therapy regulation and what it means for the revision of the pharma legislation
-
Simone Boselli (Public Affairs Director, EURORDIS) – Gene&cell therapy regulation and what it means for the revision of the pharma legislation
-
MEP Pernille Weiss (EPP, DK); MEP Radka Maxova (S&D, CZ); Victor Maertens (Government Affairs Manager, EUCOPE) – How to make Europe more attractive for gene and cell therapy development?
-
Adam Hutchings (Managing Director, Dolon Consultancy) – How to make Europe more attractive for gene and cell therapy development?
-
Christina Kyriakopoulou (Senior Policy Officer, DG RTD) How to make Europe more attractive for cell and gene therapy development?
-
Frédéric Druck (Secretary General, essencia/bio.be) How to make Europe more attractive for cell and gene therapy development?
-
Victor Maertens (Government Affairs Manager, EUCOPE) How to make Europe more attractive for cell and gene therapy development?
Files
Academic articles, position papers, studies, etc. produced by TRANSFORM Alliance members